|
X-ray Targeted Therapeutic Genes within Nanoparticles
|
5R01CA125757-06
|
$302,750
|
Hallahan, Dennis
|
WASHINGTON UNIVERSITY
|
|
Washington University Molecular Imaging Center
|
5P50CA094056-11
|
$1,765,050
|
PIWNICA-WORMS, David
|
WASHINGTON UNIVERSITY
|
|
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
|
5R01CA103986-07
|
$246,403
|
Kleinerman, Eugenie
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Use of nanogels to target delivery of siRNA to cancer cells in mice
|
1R21CA155479-01
|
$240,470
|
McDonald, John
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
|
University of Texas SPORE in Lung Cancer
|
5P50CA070907-14
|
$2,185,000
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
5P50CA100632-09
|
$2,185,000
|
Kantarjian, Hagop
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
5U01CA141556-03
|
$661,137
|
Charest, Alain
|
TUFTS MEDICAL CENTER
|
|
UCLA Scholars in Oncologic Molecular lmaging (SOMI)
|
5R25CA098010-08
|
$539,986
|
PHELPS, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
5R33CA116127-04
|
$459,850
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor-Reactive Immune Cells Generated from Drosphila Antigen Presenting Cells
|
ZIA BC 011228
|
$92,929
|
Yang, James
|
CCR (NCI)
|
|
Tumor exosomes as agents of genetic change
|
5R01CA141150-03
|
$285,005
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Transposon Mediated Gene Therapy for Colorectal Cancer
|
5R01CA120383-05
|
$290,882
|
McIvor, R
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-08
|
$278,762
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Translational Breast Cancer Research Training Program
|
5T32CA090221-09
|
$114,203
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Transgenic in vivo delivery of MDA7/IL24 for maligannt glioma therapy
|
5R01CA129489-04
|
$341,162
|
GERMANO, ISABELLE
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Transduction of T cells to improve migration to tumor
|
5R01CA116206-07
|
$500,533
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Training Program in Molecular Oncology and Immunology
|
2T32CA009161-36A1
|
$778,188
|
Levy, David
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-27
|
$615,630
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
TRAINING GRANT IN VIRAL AND CHEMICAL CARCINOGENESIS
|
5T32CA009320-27
|
$284,136
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Training Grant in Cancer Biology
|
5T32CA009126-34
|
$401,105
|
MAY, William
|
UNIVERSITY OF FLORIDA
|
|
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
|
5R01CA109446-08
|
$260,730
|
Griffith, Thomas
|
UNIVERSITY OF IOWA
|
|
Therapeutic use of let-7 and miR-34 microRNAs for the prevention and treatment of
|
5F32CA153885-02
|
$51,326
|
Kasinski, Andrea
|
YALE UNIVERSITY
|
|
Therapeutic Potential of IL-15 Plasmid Delivery to Tumors Using Electroporation
|
5R01CA122518-04
|
$101,681
|
HELLER, RICHARD
|
OLD DOMINION UNIVERSITY
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-12
|
$2,117,925
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
|
3P50CA093459-07S1
|
$87,090
|
GRIMM, ELIZABETH
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
|
5P50CA093459-07
|
$2,185,000
|
GRIMM, ELIZABETH
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-12
|
$1,487,860
|
Herschman, Harvey
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
THE THERAPY OF AML
|
5P01CA055164-19
|
$2,401,083
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Roles of HBXAP Gene in Ovarian Cancer
|
5R01CA129080-04
|
$330,091
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
The Role of Fbxw7 in genetic instability and cancer
|
5R01CA116481-05
|
$345,303
|
Mao, Jian-Hua
|
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
5R01CA140655-02
|
$310,970
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
The in vivo role of the mitochondrial p53 cell death program
|
5R01CA060664-16
|
$266,225
|
MOLL, UTE
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
7R01CA142873-02
|
$49,462
|
BASTIAN, BORIS
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
The Development of the Domestic Cat as an Animal Model for Genetic Analysis
|
ZIA BC 005385
|
$313,019
|
O'Brien, Stephen
|
CCR (NCI)
|
|
The adoptive transfer of gene-modified T cells as a cell therapy for lymphoma
|
5K08CA148821-02
|
$168,661
|
Davila, Marco
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Texas Center for Cancer Nanomedicine
|
5U54CA151668-02
|
$2,579,927
|
Gorenstein, David
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
TCR Gene Modified T Cells for Adoptive Immunotherapy
|
1P01CA154778-01A1
|
$2,032,647
|
NISHIMURA, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
|
TCR Engineering of Quiescent Primary Human T Cells
|
5R21CA153789-02
|
$155,594
|
NISHIMURA, MICHAEL
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
TCR Affinity and Therapeutic Efficacy of T Cells
|
5R01CA104947-05
|
$284,456
|
NISHIMURA, MICHAEL
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Targeting Translation Control in Malignant Glioma
|
5R01CA124756-05
|
$258,757
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-05
|
$270,405
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Targeting of STAT3 Signaling Enhances Efficacy of Breast Cancer Immunotherapy
|
5R01CA134364-03
|
$382,222
|
REISFELD, RALPH
|
SCRIPPS RESEARCH INSTITUTE
|
|
Targeting Leukemic Stem Cells
|
5R01CA138211-04
|
$419,335
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS
|
5R01CA156690-02
|
$316,215
|
Oltz, Eugene
|
WASHINGTON UNIVERSITY
|
|
Targeting Entry of Retroviral/Lentiviral Vectors
|
3R01CA049932-19S1
|
$61,330
|
ROTH, MONICA
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Targeting Entry of Retroviral/Lentiviral Vectors
|
5R01CA049932-19
|
$277,833
|
ROTH, MONICA
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Targeting Cancer with Telomerase Interference
|
5K08CA126983-05
|
$131,220
|
Goldkorn, Amir
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
1R01CA154697-01A1
|
$517,924
|
Curiel, David
|
WASHINGTON UNIVERSITY
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-03
|
$543,264
|
Riddell, Stanley
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Polymer-Adenovirus Hybrids for Ablation of Bladder Cancer Disease
|
5R21CA143505-02
|
$151,089
|
Rege, Kaushal
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|